NDOI Stock Overview

A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. More details

NDOI fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	2/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (0.5x) is below the US market (18.3x)

Became profitable this year

Risk Analysis

High level of non-cash earnings

Interest payments are not well covered by earnings

My Notes

Capture your thoughts, links and company narrative

Endo Inc. Competitors

Ligand Pharmaceuticals

NasdaqGM:LGND

US$2.2b

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$2.0b

Innoviva

NasdaqGS:INVA

US$1.1b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$1.9b

Price History & Performance

Summary of share price highs, lows and changes for Endo
Historical stock prices
Current Share Price	US$24.00
52 Week High	US$29.75
52 Week Low	US$22.50
Beta	0
1 Month Change	-2.04%
3 Month Change	-7.69%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-15.04%

Recent updates

Shareholder Returns

	NDOI	US Pharmaceuticals	US Market
7D	0%	-1.5%	-2.4%
1Y	n/a	7.9%	23.4%

Return vs Industry: Insufficient data to determine how NDOI performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how NDOI performed against the US Market.

Price Volatility

Is NDOI's price volatile compared to industry and market?
NDOI volatility
NDOI Average Weekly Movement	5.4%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: NDOI has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine NDOI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	2,931	Scott Hirsch	www.endo.com

Endo Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. It operates through four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The Branded Pharmaceuticals segment offers products for the treatment of conditions in urology, orthopedics, and endocrinology.

Endo Inc. Fundamentals Summary

How do Endo's earnings and revenue compare to its market cap?
NDOI fundamental statistics
Market cap	US$1.83b
Earnings (TTM)	US$3.37b
Revenue (TTM)	US$1.79b

0.5x

P/E Ratio

1.0x

P/S Ratio

Is NDOI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NDOI income statement (TTM)
Revenue	US$1.79b
Cost of Revenue	US$850.31m
Gross Profit	US$940.06m
Other Expenses	-US$2.43b
Earnings	US$3.37b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	44.08
Gross Margin	52.51%
Net Profit Margin	188.11%
Debt/Equity Ratio	152.4%

How did NDOI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 04:24
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Endo Inc. is covered by 44 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Richard Silver	Barclays
Gary Nachman	BMO Capital Markets Equity Research
Sumant Satchidanand Kulkarni	BofA Global Research

Endo OTCPK:NDOI Stock Report